|
|
News Breaks | | | | February 27, 2013 | | 13:05 EDT |  | MDT | Medtronic procedure reduces snoring loudness, mild to moderate OSA
In a meta-analysis of seven studies published in the January issue of Laryngoscope, Ji Ho Choi, M.D., Ph. D., and coauthors conclude that the Medtronic Pillar Procedure significantly reduced snoring loudness and mild-to-moderate obstructive sleep apnea. For their analysis of the effect of the Pillar Procedure on snoring, Choi and his colleagues used seven case-controlled studies, with a total enrollment of 174 subjects. These studies all used the post-procedure Visual Analogue Scale score compared to the pre-procedure score as their primary outcome measure. VAS is a measure of snoring intensity. The meta-analysis results indicate that the Pillar implant reduced snoring sound significantly as compared to preprocedure values with a standardized mean difference of -0.591. Study authors also analyzed the efficacy of the Pillar procedure as a single surgical procedure for the treatment of mild to moderate OSA. The seven selected studies included five case series and two placebo-controlled trials. The total number of subjects enrolled in the seven studies was 363, of which 76 were in placebo control groups. | |
|
News For MDT From The Last 14 Days Check below for free stories on MDT the last two weeks. |
|
|
| May 16, 2013 | | 13:32 EDT |  | MDT | Medtronic volatility flat into Q4 and outlook
 Subscribe for More Information | | | 10:03 EDT |  | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information | | | May 10, 2013 | | 15:49 EDT | | MDT | Medtronic defibrillators demonstrate success of shock avoidance
Subscribe for More Information | | | May 8, 2013 | | 07:38 EDT |  | MDT | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information | | | May 6, 2013 | | 09:19 EDT | | MDT | Medtronic receives FDA approval for newest cardiac devices
Medtronic announced FDA approval and U.S. launch of its newest cardiac devices: the Viva portfolio of cardiac resynchronization therapy with defibrillation, or CRT-D, devices, and the Evera portfolio of implantable cardioverter-defibrillators. | |
|
|
|
|
|
|
